vTv Therapeutics Company Profile (NASDAQ:VTVT)

About vTv Therapeutics

vTv Therapeutics logovTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VTVT
  • CUSIP:
Key Metrics:
  • Previous Close: $7.23
  • 50 Day Moving Average: $6.24
  • 200 Day Moving Average: $5.85
  • 52-Week Range: $4.84 - $8.22
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.80
  • P/E Growth: 0.00
  • Market Cap: $69.28M
  • Outstanding Shares: 9,690,000
  • Beta: 0.8
Profitability:
  • Net Margins: -1,699.13%
  • Return on Assets: -18.44%
Debt:
  • Current Ratio: 6.54%
  • Quick Ratio: 6.54%
Additional Links:
Companies Related to vTv Therapeutics:

Analyst Ratings

Consensus Ratings for vTv Therapeutics (NASDAQ:VTVT) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.33 (128.44% upside)

Analysts' Ratings History for vTv Therapeutics (NASDAQ:VTVT)
Show:
DateFirmActionRatingPrice TargetDetails
9/26/2016HC WainwrightInitiated CoverageBuy$13.00View Rating Details
8/19/2016Canaccord GenuityReiterated RatingBuy$15.00View Rating Details
12/17/2015Janney Montgomery ScottInitiated CoverageBuy$21.00View Rating Details
8/24/2015Piper Jaffray Cos.Initiated CoverageOverweight$24.00View Rating Details
8/24/2015Stifel NicolausInitiated CoverageBuy$17.00View Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for vTv Therapeutics (NASDAQ:VTVT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
8/16/2016Q216($0.47)ViewN/AView Earnings Details
5/12/2016Q1($0.54)($0.42)ViewN/AView Earnings Details
3/1/2016Q4($0.47)($0.35)$0.03 million$0.23 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for vTv Therapeutics (NASDAQ:VTVT)
Current Year EPS Consensus Estimate: $-1.49 EPS
Next Year EPS Consensus Estimate: $-1.49 EPS

Dividends

Dividend History for vTv Therapeutics (NASDAQ:VTVT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for vTv Therapeutics (NASDAQ:VTVT)
Insider Ownership Percentage: 0.17%
Institutional Ownership Percentage: 12.84%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/27/2016Paul G SavasDirectorBuy6,000$5.67$34,020.00View SEC Filing  
5/24/2016Paul G SavasDirectorBuy1,259$5.26$6,622.34View SEC Filing  
4/8/2016Ronald O PerelmanMajor ShareholderBuy10,000$4.99$49,900.00View SEC Filing  
4/5/2016Ronald O PerelmanMajor ShareholderBuy400,000$5.20$2,080,000.00View SEC Filing  
3/28/2016Paul G SavasDirectorBuy10,000$5.35$53,500.00View SEC Filing  
3/24/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.64$56,400.00View SEC Filing  
3/7/2016Paul G SavasDirectorBuy15,000$5.82$87,300.00View SEC Filing  
2/12/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.83$58,300.00View SEC Filing  
2/5/2016Ronald O PerelmanMajor ShareholderBuy10,000$6.43$64,300.00View SEC Filing  
2/4/2016Ronald O PerelmanMajor ShareholderBuy20,000$6.05$121,000.00View SEC Filing  
1/13/2016Ronald O PerelmanMajor ShareholderBuy15,000$6.41$96,150.00View SEC Filing  
12/18/2015Ronald O PerelmanMajor ShareholderBuy15,000$6.40$96,000.00View SEC Filing  
12/15/2015Noel Joseph SpiegelDirectorBuy5,710$6.20$35,402.00View SEC Filing  
10/2/2015Ronald O PerelmanMajor ShareholderBuy30,000$6.26$187,800.00View SEC Filing  
9/28/2015Ronald O PerelmanMajor ShareholderBuy40,000$6.04$241,600.00View SEC Filing  
9/25/2015Paul G SavasDirectorBuy5,000$6.62$33,100.00View SEC Filing  
9/22/2015Ronald O PerelmanMajor ShareholderBuy24,000$6.82$163,680.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for vTv Therapeutics (NASDAQ:VTVT)
DateHeadline
finance.yahoo.com logovTv Therapeutics to Present at the Rodman & Renshaw Global Investment Conference (NASDAQ:VTVT)
finance.yahoo.com - September 8 at 11:57 AM
News IconvTv Therapeutics Completes Enrollment of Part A of Pivotal Phase 3 Trial Evaluating Azeliragon ... (NASDAQ:VTVT)
www.biomedreports.com - September 7 at 11:55 AM
publicnow.com logovTv Therapeutics Completes Enrollment of Part A of Pivotal Phase 3 Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease (NASDAQ:VTVT)
www.publicnow.com - September 7 at 11:55 AM
News IconvTv Therapeutics To Present At The (NASDAQ:VTVT)
www.biospace.com - September 2 at 7:51 PM
finance.yahoo.com logovTv Therapeutics to Present at the International Psychogeriatric Association International Congress (NASDAQ:VTVT)
finance.yahoo.com - September 2 at 8:02 AM
publicnow.com logovTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes (NASDAQ:VTVT)
www.publicnow.com - August 16 at 11:33 AM
wsj.com logo[$$] Clinical Development News, Aug. 8-12 (NASDAQ:VTVT)
www.wsj.com - August 12 at 8:20 PM
biz.yahoo.com logoVTV THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:VTVT)
biz.yahoo.com - August 11 at 11:40 AM
News IconvTv Therapeutics Announces Positive Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Diabetes (NASDAQ:VTVT)
www.enhancedonlinenews.com - August 10 at 11:27 AM
News IconvTv Therapeutics Announces Positive Initial Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Dia... (NASDAQ:VTVT)
ih.advfn.com - August 10 at 11:27 AM
streetinsider.com logovTv Therapeutics (VTVT) Announces TTP399 Phase 2b Met Primary Endpoint in T2D (NASDAQ:VTVT)
www.streetinsider.com - August 10 at 11:27 AM
publicnow.com logoCORRECTING and REPLACING vTv Therapeutics Announces Positive Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Diabetes (NASDAQ:VTVT)
www.publicnow.com - August 10 at 11:27 AM
sg.finance.yahoo.com logoVTv Therapeutics reports 2Q loss (NASDAQ:VTVT)
sg.finance.yahoo.com - August 3 at 11:34 AM
biz.yahoo.com logoVTV THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:VTVT)
biz.yahoo.com - August 2 at 8:37 PM
tmcnet.com logovTv Therapeutics Announces Presentation of Phase 2b Azeliragon Results at the 2016 Alzheimer's Association International Conference (AAIC) (NASDAQ:VTVT)
www.tmcnet.com - July 27 at 8:40 PM
streetinsider.com logovTv Therapeutics (VTVT) Announces Presentation of Phase 2b Azeliragon Results at AAIC (NASDAQ:VTVT)
www.streetinsider.com - July 27 at 8:40 PM
publicnow.com logovTv Therapeutics Announces Presentation of Phase 2b Azeliragon Results at the 2016 Alzheimer’s Association International Conference (AAIC) (NASDAQ:VTVT)
www.publicnow.com - July 27 at 5:38 PM
capitalcube.com logoETF’s with exposure to vTv Therapeutics, Inc. : July 22, 2016 (NASDAQ:VTVT)
www.capitalcube.com - July 22 at 3:28 PM
4-traders.com logovTv Therapeutics : U.S. Patents Awarded to Inventors in Maryland (July 20) (NASDAQ:VTVT)
www.4-traders.com - July 20 at 9:17 PM
tmcnet.com logovTv Therapeutics Announces Phase 2b Azeliragon Data Selected for Oral Presentation at the 2016 Alzheimer's Association International Conference (NASDAQ:VTVT)
www.tmcnet.com - July 14 at 11:50 AM
publicnow.com logovTv Therapeutics Announces Phase 2b Azeliragon Data Selected for Oral Presentation at the 2016 Alzheimer’s Association International Conference (NASDAQ:VTVT)
www.publicnow.com - July 14 at 9:28 AM
publicnow.com logovTv Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference (NASDAQ:VTVT)
www.publicnow.com - July 6 at 7:31 AM
publicnow.com logovTv Therapeutics Presents Positive Results from a Pilot Study of its Glucokinase Activator at American Diabetes Association 76th Scientific Sessions (NASDAQ:VTVT)
www.publicnow.com - June 14 at 7:29 AM
capitalcube.com logovTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016 (NASDAQ:VTVT)
www.capitalcube.com - June 7 at 11:10 AM
News IconVtv Therapeutics Class A (NASDAQ:VTVT) Sellers Increased By 2.17% Their Shorts - HNN (NASDAQ:VTVT)
hintsnewsnetwork.com - May 30 at 7:36 PM
News IconEarnings Review and Stock Rundown for vTv Therapeutics Inc (NASDAQ:VTVT) - Wall Street Hints and News (NASDAQ:VTVT)
hintsnewsnetwork.com - May 24 at 1:20 PM
kcregister.com logoBiotechnology Lows: vTv Therapeutics Inc. (NASDAQ:VTVT), Jaguar Animal Health (NASDAQ:JAGX), QLT Inc ... - KC Register (NASDAQ:VTVT)
www.kcregister.com - May 23 at 1:35 PM
kcregister.com logoBest Stocks: Mad Catz Interactive (NYSEMKT:MCZ), vTv Therapeutics Inc. (NASDAQ:VTVT), Ultratech, (NASDAQ:UTEK ... - KC Register (NASDAQ:VTVT)
www.kcregister.com - May 23 at 1:35 PM
tradecalls.org logoRevenue Update on vTv Therapeutics Inc(NASDAQ:VTVT) - Trade Calls (NASDAQ:VTVT)
www.tradecalls.org - May 21 at 1:54 PM
News IconShare Recap and Earnings Focus on vTv Therapeutics Inc (NASDAQ:VTVT) - Wall Street Hints and News (NASDAQ:VTVT)
hintsnewsnetwork.com - May 18 at 1:43 PM
biz.yahoo.com logoVTV THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:VTVT)
biz.yahoo.com - May 16 at 4:02 PM
publicnow.com logovTv Therapeutics Reports First Quarter Financial and Operational Results (NASDAQ:VTVT)
www.publicnow.com - May 12 at 5:27 PM
sg.finance.yahoo.com logoVTv Therapeutics reports 1Q loss (NASDAQ:VTVT)
sg.finance.yahoo.com - May 12 at 4:52 PM
News IconvTv Therapeutics Inc (NASDAQ:VTVT) Share Rating Recap - B.O.D.Y Confidential (NASDAQ:VTVT)
www.bodyconfidential.com - April 27 at 1:32 PM
News IconvTv Therapeutics Inc (NASDAQ:VTVT) Analyst Rating Review - B.O.D.Y Confidential (NASDAQ:VTVT)
www.bodyconfidential.com - April 23 at 12:47 PM
News IconvTv Therapeutics Inc (NASDAQ:VTVT) Share Rating Recap - The Post (NASDAQ:VTVT)
www.bibeypost.com - April 22 at 1:31 PM
News IconRecently Changed Price Targets On VTv Therapeutics Inc. (VTVT) - Risers & Fallers (NASDAQ:VTVT)
www.risersandfallers.com - April 22 at 1:31 PM
News IconBroker Roundup For VTv Therapeutics Inc. (VTVT) - Share Trading News (NASDAQ:VTVT)
www.sharetrading.news - April 21 at 1:21 PM
nasdaq.com logoEither Analysts Got The Components Wrong or Russell 2000 Headed 12% Higher (NASDAQ:VTVT)
www.nasdaq.com - April 20 at 12:54 PM
publicnow.com logovTv Therapeutics Presents Data on Two Diabetes Candidates at Keystone Symposia on New Therapeutics for Diabetes and Obesity (NASDAQ:VTVT)
www.publicnow.com - April 20 at 7:10 AM
News IconDoes vTv Therapeutics Inc Have Any Gas After Forming This Wedge Down Chart Pattern? - RiversideGazette.com (NASDAQ:VTVT)
www.riversidegazette.com - April 19 at 12:51 PM
publicnow.com logovTv Therapeutics Announces Presentations on its Diabetes Product Candidates TTP273 and TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity (NASDAQ:VTVT)
www.publicnow.com - April 12 at 7:24 AM
News IconPtc Therapeutics Incorporated (NASDAQ:PTCT) Short Interest Decreased By 3.37% (NASDAQ:VTVT)
ambienteja.info - April 10 at 1:01 PM
gurufocus.com logoInsiders Keep on Selling Facebook and Ford (NASDAQ:VTVT)
www.gurufocus.com - April 8 at 1:00 PM
capitalcube.com logovTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: 2015 By the Numbers (NASDAQ:VTVT)
www.capitalcube.com - April 6 at 9:50 AM
publicnow.com logovTv Therapeutics to Present at the 15th Annual Needham Healthcare Conference (NASDAQ:VTVT)
www.publicnow.com - April 6 at 7:29 AM
biz.yahoo.com logoVTV THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:VTVT)
biz.yahoo.com - March 21 at 4:01 PM
finance.yahoo.com logoVTV THERAPEUTICS INC. Financials (NASDAQ:VTVT)
finance.yahoo.com - March 10 at 1:04 PM
biz.yahoo.com logoVTV THERAPEUTICS INC. Files SEC form 10-K, Annual Report (NASDAQ:VTVT)
biz.yahoo.com - March 4 at 11:38 AM
finance.yahoo.com logoHow Did Microsoft’s Stock Respond to 2Q16 Results? (NASDAQ:VTVT)
finance.yahoo.com - February 9 at 12:06 PM

Social

vTv Therapeutics (NASDAQ:VTVT) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff